Latest Oncology News

Roundtable Discussion: Pagel Walks Through Treatment Choices in Chronic Lymphocytic Leukemia

January 16, 2022

During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.

Hegde Considers Combination Regimens for NSCLC With PD-L1 Expression 1% or Higher

January 16, 2022

During a Targeted Oncology live event, Aparna Hegde, MD, discussed the results of the KEYNOTE-189 study of pemetrexed and pembrolizumab, the KEYNOTE-042 study of single-agent pembrolizumab, and the CheckMate 227 study of nivolumab and ipilimumab in patients with non–small cell lung cancer.